Press release
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Landscape Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Relapsed/Refractory Acute Myeloid Leukemia Pipeline. Dive into DelveInsight's comprehensive report today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
* In July 2025, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS announced a pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CANCER-01-03, Project ID 101104421).
* In July 2025, ARCE Therapeutics Inc. conducted a phase I/2 study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
* DelveInsight's Relapsed/Refractory Acute Myeloid Leukemia Pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
* The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen and others.
* Promising Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapies such as APG-2575, Cytarabine, Venetoclax, Tagraxofusp, Cladribine (CLAD), Venetoclax Oral Tablet, Selinexor, Idarubicin and others.
Stay ahead with the most recent pipeline outlook for Relapsed/Refractory Acute Myeloid Leukemia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Relapsed/Refractory Acute Myeloid Leukemia Treatment Drugs [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile
* APG-2575: Ascentage Pharma
APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenstrom macroglobulinemia, acute myeloid leukemia, follicular lymphoma).
* CLN 049: Cullinan Oncology
CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.
* Lanraplenib: Kronos Bio
Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.
The Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Relapsed/Refractory Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia Treatment.
* Relapsed/Refractory Acute Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Relapsed/Refractory Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsed/Refractory Acute Myeloid Leukemia market
Explore groundbreaking therapies and clinical trials in the Relapsed/Refractory Acute Myeloid Leukemia Pipeline. Access DelveInsight's detailed report now! @ New Relapsed/Refractory Acute Myeloid Leukemia Drugs [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Relapsed/Refractory Acute Myeloid Leukemia Companies
Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen and others.
Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Relapsed/Refractory Acute Myeloid Leukemia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
* Coverage- Global
* Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen and others.
* Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapies- APG-2575, Cytarabine, Venetoclax, Tagraxofusp, Cladribine (CLAD), Venetoclax Oral Tablet, Selinexor, Idarubicin and others.
* Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Relapsed/Refractory Acute Myeloid Leukemia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Relapsed/Refractory Acute Myeloid Leukemia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Relapsed/refractory acute myeloid leukemia (AML): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Relapsed/refractory acute myeloid leukemia (AML)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* APG-2575: Ascentage Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CLN 049: Cullinan Oncology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Relapsed/refractory acute myeloid leukemia (AML) Key Companies
* Relapsed/refractory acute myeloid leukemia (AML) Key Products
* Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
* Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
* Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
* Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
* Relapsed/refractory acute myeloid leukemia (AML) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=relapsedrefractory-acute-myeloid-leukemia-pipeline-landscape-appears-robust-with-50-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/Refractory Acute Myeloid Leukemia Pipeline Landscape Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4107174 • Views: …
More Releases from ABNewswire
H3N2 Infection Pipeline Appears Robust With 15+ Key Pharma Companies Actively Wo …
DelveInsight's, "H3N2 Infection Pipeline Insight, 2025," report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 Infection pipeline landscape. It covers the H3N2 Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the H3N2 Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in H3N2…
Obesity Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working i …
DelveInsight's "Obesity Pipeline Insight 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Othe besity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive…
Chronic Hepatitis B Virus Pipeline Appears Robust With 50+ Key Pharma Companies …
DelveInsight's, "Chronic Hepatitis B Virus Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Chronic Hepatitis B Virus pipeline landscape. It covers the Chronic Hepatitis B Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest…
Breast Cancer Pipeline Appears Robust With 100+ Key Pharma Companies Actively Wo …
DelveInsight's, "Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 100+ Breast Cancer companies and 120+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest…
More Releases for Acute
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Us Post-Acute Care Market
The "Us Post-Acute Care Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Us Post-Acute Care Market, 2024-2031
Verified Market Research's most recent report, "Us Post-Acute Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides…
Acute Vulvovaginal Candidiasis Market Beyond Douching: New Treatment Options Dri …
Acute Vulvovaginal Candidiasis Market worth $ 485.54 Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acute Vulvovaginal Candidiasis Market- by Drug Type (Clotrimazole, Nystatin, Fluconazole, , Terbinafine, Terconazole and Other Drug Types), Route of Administration (Oral, Intravenous and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast…
Acute Myeloid Leukemia Pipeline Unveiled: Pioneering Efforts in Acute Myeloid Le …
The Acute Myeloid Leukemia Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Acute Myeloid Leukemia treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the pipeline landscape and fostering the potential growth of Acute Myeloid Leukemia therapeutic advancements.
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
• DelveInsight's Acute Myeloid Leukemia pipeline…
Acute Care Needleless Connectors Market - Ensuring safe and efficient medication …
Newark, New Castle, USA: The "Acute Care Needleless Connectors Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acute Care Needleless Connectors Market: https://www.growthplusreports.com/report/acute-care-needleless-connectors-market/7813
This latest report researches the…
Acute Myeloid Leukemia Market - Shattering Limits, Renewing Hope: Advancing the …
Newark, New Castle, USA - new report, titled Acute Myeloid Leukemia Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Acute Myeloid Leukemia market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Acute Myeloid Leukemia market. The report offers an overview of…
